USE OF PYROGLUTAMYL-GLUTAMYL-PROLYLAMIDE (EEP) FOR NEUROLOGICAL AND NEUROBEHAVIORAL DISORDERS

Inventors: Albert Sattin, 1811 Barry Ave, Los Angeles, CA (US) 90025; Albert E. Pekary, 4022 Globe Ave, Culver City, CA (US) 90230; Robert L. Lloyd, 1533 Fern Ave, Duluth, MN (US) 55805

Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

Filed: Oct. 9, 1998

Related U.S. Application Data
Provisional application No. 60/062,142, filed on Oct. 9, 1997.

Int. Cl. A61K 38/06; C07K 5/093

U.S. Cl. 514/18; 530/331

Field of Search 514/18; 530/331

References Cited
U.S. PATENT DOCUMENTS
3,737,549 A * 6/1973 Plotnikoff .................................. 424/274
4,600,636 A * 8/1986 Engel .................................. 424/274
5,244,884 A * 9/1993 Spatola et al. .......................... 530/331

OTHER PUBLICATIONS


(Primary Examiner—Christopher S. F. Low
Assistant Examiner—Anish Gupta
(74) Attorney, Agent, or Firm—Stephen A. Slusher; Deborah A. Peacock; Jeffrey D. Myers

ABSTRACT
A tri-peptide drug for treatment of neurological and neurobehavioral disorders of a mammal, such drug being derived from the following formula: pGlu-X-Pro-NH2, wherein the internal amino acid (X) is a non-histidine amino acid. Methods of treatment of neurological disorders using the tri-peptide, including as an adjunct, synergist or stand-alone therapy, in oral, parenteral, intranasal, transcutaneous, or rectal forms.

6 Claims, 3 Drawing Sheets